finance.yahoo.com / Yahoo! Finance
npub1vap…wc3n
2024-11-23 06:13:24
Author Public Key
npub1vap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aessgrwc3nPublished at
2024-11-23 06:13:24Event JSON
{
"id": "8530dd5d2cac0e00f063c7860caa433d3378907d1fb6b66271451c27aba1f77f",
"pubkey": "6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"created_at": 1732342404,
"kind": 1,
"tags": [
[
"r",
"https://finance.yahoo.com/news/halozyme-withdraws-evotec-bid-rebuff-171258773.html"
],
[
"subject",
"Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook"
],
[
"published_at",
"1732295578"
],
[
"image",
"https://media.zenfs.com/en/Benzinga/aafb09ec89647b56a691099922c789ab"
],
[
"p",
"6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://media.zenfs.com/en/Benzinga/aafb09ec89647b56a691099922c789ab"
],
[
"t",
"other:perspective"
],
[
"summary",
"Halozyme Therapeutics announced that it is withdrawing its proposal to acquire Evotec SE for 11 euro per share in cash, citing Evotec's desire to remain an independent company. The company had been trying to acquire Evotec for several months, but its efforts were unsuccessful. Despite this, Halozyme reaffirmed its strong business outlook, with guidance for 2024 signaling continued growth."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqvap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aesst3mr8r\nhttps://media.zenfs.com/en/Benzinga/aafb09ec89647b56a691099922c789ab\n\nhttps://finance.yahoo.com/news/halozyme-withdraws-evotec-bid-rebuff-171258773.html",
"sig": "6a49ed609e638591fefff6a3bb5704dc7eccc96d1088ff1cd7914417c71de5b0660fcb7d82c709c0f70ce7a417f2ca1f1c81c2d29e3d77af9856c956340e7976"
}